HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS

• Main Authors: JORDAN S. FRIDMAN, THOMAS P. MADUSKUIE, LOUIS STORACE, JAMES D. RODGERS, NIKOO FALAHATPISHEH, KRISHNA VADDI, HAISHENG WANG, STACEY SHEPARD, MARIA RAFALSKI, ARGYRIOS G. ARVANITIS, RAVI KUMAR JALLURI
• Format: Patent
• Language: Croatian; English
• Published: 31.01.2012
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Spoj formule I: ili njegova farmaceutski prihvatljiva sol, naznačen time da: T, U, i V su nezavisno odabrani od O, S, N, CR5, i NR6;pri čemu 5-člani prsten koji formira atom ugljika, atom dušika, U, T, i V je aromatski; X je N ili CR4;n je 0; ilin je I i Y je C1-8alkilen, C2-8alkenilen, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, ili (CR11R12)pOC(O)(CR11R12)q, pri čemu navedeni C1-8alkilen ili C2-8alkenilen, je proizvoljno supstituiran sa 1, 2, ili 3 halo, OH, CN, amino, C1-4alkilamino, ili C2-8dialkilamino; Z je aril, cikloalkil, heteroaril, ili heterocikloalkil, svaki proizvoljno supstituiran sa 1, 2, 3, 4, 5, ili 6 nezavisnih supstituenata odabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, C1-4 cijanoalkila, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, i S(O)2NRcRd;Cy1 je nezavisno odabran od arila, heteroarila, cikloalkila, i heterocikloalkila, svaki proizvoljno supstituiran sa 1, 2, 3, 4 ili 5 supstituenata nezavisno odabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORa, SRa, C(O)Rb , C(O)NRcRd", C(O)ORa", OC(O)Rb", OC(O)NRc"Rd", NRc" Rd", NRc"C(O)Rb", NRc"C(O)ORa" S(O)Rb", S(O)NRcRd", S(O)2Rb", i S(O)2NRc"Rd";R4 je H; R5 je H, halo, C1-4alkil, C2-4alkenil, C2-4alkinil, C1-4haloalkil, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7,OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10 S(O)2R8, NR9S(O)2R8 ili S(O)2NRR10;R6 je H, C1-4alkil, C2-4alkenil, C2-4alkinil, C1-4haloalkil, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, ili S(O)2NR9R10;R7 je H, C1-6alkil, C1-6haloalkil, C2-6alkenil, C2-6alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil; R8 je H, C1-6alkil, C1-6haloalkil, C2-6alkenil, C2-6alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil; R9 i R10 su nezavisno odabrani od H, C1-10alkila, C1-6haloalkila, C2-6alkenila, C2-6alkinila, The present invention provides the use of the following compounds for the preparation of a medicament for use in the treatment of a viral disease.